Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PI-CaP study of PIPAC chemotherapy for peritoneal carcinomatosis
2015-000866-72Phase 2Completed
- Sponsor
- Fondazione del Piemonte per l'Oncologia
- Start
- Dec 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin, cisplatin and doxorubicin in peritoneal carcinomatosis (PC), colorectal cancer (CRC), ovarian cancer and 2 more (2 cohorts), sponsored by Fondazione del Piemonte per l'Oncologia. Primary endpoint: Overall Response Rate. Started Dec 2020; status: completed.
02
Drugs
oxaliplatincisplatindoxorubicin
03
Conditions
peritoneal carcinomatosis (PC)colorectal cancer (CRC)ovarian cancergastric cancer (GC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2015-000866-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000866-72.